» Articles » PMID: 34052112

Advances in Automated Cell Washing and Concentration

Overview
Journal Cytotherapy
Publisher Elsevier
Date 2021 May 30
PMID 34052112
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The successful commercialization of cell therapies requires thorough planning and consideration of product quality, cost and scale of the manufacturing process. The implementation of automation can be central to a robust and reproducible manufacturing process at industrialized scales. There have been a number of wash-and-concentrate devices developed for cell manufacturing. These technologies have arisen from transfusion medicine, hematopoietic stem cell and biologics manufacturing where operating mechanisms are distinct from manual centrifugation. This review describes the historical origin and fundamental technologies underlying each currently available wash-and-concentrate device as well as their relative advantages and disadvantages in cell therapy applications. Understanding the specific attributes and limitations of these technologies is essential to optimizing cell therapy manufacturing.

Citing Articles

The need for smart microalgal bioprospecting.

Labara Tirado J, Herdean A, Ralph P Nat Prod Bioprospect. 2025; 15(1):7.

PMID: 39815030 PMC: 11735771. DOI: 10.1007/s13659-024-00487-3.


Optimizing cryopreservation strategies for scalable cell therapies: A comprehensive review with insights from iPSC-derived therapies.

Dobruskin M, Toner G, Kander R Biotechnol Prog. 2024; 40(6):e3504.

PMID: 39268839 PMC: 11659802. DOI: 10.1002/btpr.3504.


Recent clinical researches and technological development in TIL therapy.

Matsueda S, Chen L, Li H, Yao H, Yu F Cancer Immunol Immunother. 2024; 73(11):232.

PMID: 39264449 PMC: 11393248. DOI: 10.1007/s00262-024-03793-4.


Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance.

Killela P, Herrity K, Frontier L, Horton R, Kurtzberg J, Vant Hof W Stem Cells Transl Med. 2024; 13(9):843-847.

PMID: 39169677 PMC: 11386209. DOI: 10.1093/stcltm/szae048.


Promises and challenges of a decentralized CAR T-cell manufacturing model.

Shah M, Krull A, ODonnell L, De Lima M, Bezerra E Front Transplant. 2024; 2:1238535.

PMID: 38993860 PMC: 11235344. DOI: 10.3389/frtra.2023.1238535.